ACE and cancer: Identification of angiotensin II as a crucial regulator of cancer-induced extramedullary hematopoiesis raised the question whether angiotensin-converting enzyme (ACE) inhibitors, widely used to treat hypertension, could suppress heightened extramedullary monocyte production and subsequent macrophage accumulation in tumors (77).